These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 2883885

  • 1. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [Abstract] [Full Text] [Related]

  • 2. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR, Tankanow RM, Nostrant TT.
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [Abstract] [Full Text] [Related]

  • 3. Famotidine in the USA: a review of efficacy studies.
    Gitnick G.
    J Int Med Res; 1989 Apr; 17 Suppl 1():17A-24A. PubMed ID: 2566539
    [Abstract] [Full Text] [Related]

  • 4. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM, Clissold SP.
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [Abstract] [Full Text] [Related]

  • 5. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT.
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [Abstract] [Full Text] [Related]

  • 6. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM, Vinayek R, Maton PN, Wank SA, Gardner JD, Jensen RT.
    J Clin Gastroenterol; 1987 Apr; 9 Suppl 2():23-5. PubMed ID: 2887615
    [Abstract] [Full Text] [Related]

  • 7. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT.
    Am J Med; 1986 Oct 24; 81(4B):49-59. PubMed ID: 2877575
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W.
    J Int Med Res; 1989 Oct 24; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [Abstract] [Full Text] [Related]

  • 9. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
    Thomson AB.
    Hepatogastroenterology; 1990 Jul 24; 37 Suppl 1():18-28. PubMed ID: 1976583
    [Abstract] [Full Text] [Related]

  • 10. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S, Clausi GG, Farinelli M, Santucci L, Farroni F, Pelli MA, Morelli A.
    Am J Gastroenterol; 1988 Dec 24; 83(12):1371-5. PubMed ID: 2904218
    [Abstract] [Full Text] [Related]

  • 11. Clinical review of histamine2 receptor antagonists.
    Lipsy RJ, Fennerty B, Fagan TC.
    Arch Intern Med; 1990 Apr 24; 150(4):745-51. PubMed ID: 1970232
    [Abstract] [Full Text] [Related]

  • 12. [Nizatidine].
    Romero M, Franzosi MG.
    Medicina (Firenze); 1989 Apr 24; 9(1):93-6. PubMed ID: 2567957
    [Abstract] [Full Text] [Related]

  • 13. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
    Bianchi Porro G.
    Digestion; 1985 Apr 24; 32 Suppl 1():62-9. PubMed ID: 2866137
    [Abstract] [Full Text] [Related]

  • 14. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN, Gardner JD, Jensen RT.
    Gastroenterol Clin North Am; 1989 Dec 24; 18(4):847-63. PubMed ID: 2575602
    [Abstract] [Full Text] [Related]

  • 15. Famotidine in the treatment of duodenal ulcers resistant to other histamine H2-receptor antagonists.
    Chen PH, Wang TH, Wang CY, Chen CY, Cheng TC, Tsai YT, Siauw CP, Yang KC, Chen GH, Sung JL.
    J Int Med Res; 1989 Dec 24; 17 Suppl 1():25A-31A. PubMed ID: 2566541
    [Abstract] [Full Text] [Related]

  • 16. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
    Langtry HD, Grant SM, Goa KL.
    Drugs; 1989 Oct 24; 38(4):551-90. PubMed ID: 2573505
    [Abstract] [Full Text] [Related]

  • 17. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
    Freston JW.
    Am J Gastroenterol; 1987 Dec 24; 82(12):1242-9. PubMed ID: 2891294
    [Abstract] [Full Text] [Related]

  • 18. [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
    Baglioni A, Barbara L, Bianchi-Porro G, Blasi A, Canelli B, Cheli R, Dal Monte R, Dammann HG, Francavilla A, Hentschel E.
    Z Gastroenterol; 1985 Dec 24; 23(12):665-9. PubMed ID: 2868581
    [Abstract] [Full Text] [Related]

  • 19. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G, Amplaz S, Benvenuti S, Bertozzo A.
    G Clin Med; 1990 Dec 24; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract] [Full Text] [Related]

  • 20. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
    Dammann HG, Müller P, Simon B, Kommerell B.
    Z Gastroenterol; 1984 Jun 24; 22(6):318-20. PubMed ID: 6147052
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.